Integration of cell therapies and bispecific antibodies into the treatment pathway of relapsed diffuse large B-cell lymphoma

被引：11
作者：
Rampotas, Alexandros [2 ]
Sangha, Gina [2 ]
Collins, Graham P. [1 ]
机构：
[1] Oxford Univ Hosp NHS Fdn Trust, Churchill Hosp, Old Rd, Oxford OX3 7LE, England
[2] Oxford Univ Hosp NHS Fdn Trust, Oxford, England
来源：
THERAPEUTIC ADVANCES IN HEMATOLOGY | 2021年 / 12卷
关键词：
CHIMERIC ANTIGEN RECEPTOR; SINGLE-ARM; OPEN-LABEL; SALVAGE REGIMENS; RITUXIMAB; TRANSPLANTATION; MULTICENTER; CHEMOTHERAPY; SURVIVAL; OUTCOMES;
D O I：
10.1177/20406207211053120
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：12
相关论文
共 57 条
[1]   Updated safety and long term clinical outcomes in TRANSCEND NHL 001, pivotal trial of lisocabtagene maraleucel (JCAR017) in R/R aggressive NHL. [J].
Abramson, Jeremy S. ;
Gordon, Leo I. ;
Palomba, Maria Lia ;
Lunning, Matthew Alexander ;
Arnason, Jon E. ;
Forero-Torres, Andres ;
Wang, Michael ;
Maloney, David G. ;
Sehgal, Alison ;
Andreadis, Charalambos ;
Purev, Enkhtsetseg ;
Solomon, Scott R. ;
Ghosh, Nilanjan ;
Albertson, Tina M. ;
Xie, Benhuai ;
Garcia, Jacob ;
Siddiqi, Tanya .
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[2]  
Abramson JS, 2017, BLOOD, V130
[3]   Prognostic significance of MYC, BCL2, and BCL6 rearrangements in patients with diffuse large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab [J].
Akyurek, Nalan ;
Uner, Aysegul ;
Benekli, Mustafa ;
Barista, Ibrahim .
CANCER, 2012, 118 (17) :4173-4183
[4]   Efficacy and safety of second-generation CAR T-cell therapy in diffuse large B-cell lymphoma: A meta-analysis [J].
Al-Mansour, Mubarak ;
Al-Foheidi, Meteb ;
Ibrahim, Ezzeldin .
MOLECULAR AND CLINICAL ONCOLOGY, 2020, 13 (04) :1-14
[5]   Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling [J].
Alizadeh, AA ;
Eisen, MB ;
Davis, RE ;
Ma, C ;
Lossos, IS ;
Rosenwald, A ;
Boldrick, JG ;
Sabet, H ;
Tran, T ;
Yu, X ;
Powell, JI ;
Yang, LM ;
Marti, GE ;
Moore, T ;
Hudson, J ;
Lu, LS ;
Lewis, DB ;
Tibshirani, R ;
Sherlock, G ;
Chan, WC ;
Greiner, TC ;
Weisenburger, DD ;
Armitage, JO ;
Warnke, R ;
Levy, R ;
Wilson, W ;
Grever, MR ;
Byrd, JC ;
Botstein, D ;
Brown, PO ;
Staudt, LM .
NATURE, 2000, 403 (6769) :503-511
[6]   Autologous lymphapheresis for the production of chimeric antigen receptor T cells [J].
Allen, Elizabeth S. ;
Stroncek, David F. ;
Ren, Jiaqiang ;
Eder, F. ;
West, Kamille A. ;
Fry, Terry J. ;
Lee, Daniel W. ;
Mackall, Crystal L. ;
Conry-Cantilena, Cathy .
TRANSFUSION, 2017, 57 (05) :1133-1141
[7]   Odronextamab (REGN1979), a Human CD20 x CD3 Bispecific Antibody, Induces Durable, Complete Responses in Patients with Highly Refractory B-Cell Non-Hodgkin Lymphoma, Including Patients Refractory to CAR T Therapy [J].
Bannerji, Rajat ;
Allan, John N. ;
Arnason, Jon E. ;
Brown, Jennifer R. ;
Advani, Ranjana ;
Ansell, Stephen M. ;
O'Brien, Susan M. ;
Duell, Johannes ;
Martin, Peter ;
Joyce, Robin M. ;
Li, Jingjin ;
Flink, Dina M. ;
Zhu, Min ;
Weinreich, David M. ;
Yancopoulos, George D. ;
Sirulnik, Andres ;
Chaudhry, Aafia ;
Ambati, Srikanth R. ;
Topp, Max S. .
BLOOD, 2020, 136
[8]   Rearrangement of MYC Is Associated With Poor Prognosis in Patients With Diffuse Large B-Cell Lymphoma Treated in the Era of Rituximab [J].
Barrans, Sharon ;
Crouch, Simon ;
Smith, Alex ;
Turner, Kathryn ;
Owen, Roger ;
Patmore, Russell ;
Roman, Eve ;
Jack, Andrew .
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (20) :3360-3365
[9]   Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15 [J].
Brentjens, RJ ;
Latouche, JB ;
Santos, E ;
Marti, F ;
Gong, MC ;
Lyddane, C ;
King, PD ;
Larson, S ;
Weiss, M ;
Rivière, I ;
Sadelain, M .
NATURE MEDICINE, 2003, 9 (03) :279-286
[10]   Chimeric antigen receptor T-cell therapies for lymphoma [J].
Brudno, Jennifer N. ;
Kochenderfer, James N. .
NATURE REVIEWS CLINICAL ONCOLOGY, 2018, 15 (01) :31-46
123456